Recommendation for Shingrix in Young Adults with UC on Immunosuppressants
Yes, young adults with ulcerative colitis on immunosuppressive therapy should receive Shingrix (recombinant zoster vaccine), regardless of their varicella seropositivity status from prior chickenpox vaccination. 1, 2
Guideline-Based Rationale
The Canadian Association of Gastroenterology (2021) provides a conditional recommendation for recombinant zoster vaccine in adult IBD patients younger than 50 years of age (low certainty of evidence), while giving a strong recommendation for those 50 years and older (moderate certainty of evidence) 1. The ECCO guidelines (2021) are even more explicit, stating that recombinant herpes zoster vaccine is the preferred vaccine for patients with IBD and remains recommended for patients receiving immunosuppressive therapy 2.
Why This Matters for Young Immunosuppressed Patients
The risk profile changes dramatically with immunosuppression:
- IBD patients have elevated herpes zoster risk: Crohn's disease patients have a relative risk of 1.74 (95% CI: 1.57-1.92) and UC patients 1.40 (95% CI: 1.31-1.50) compared to the general population 2
- Immunosuppression amplifies this risk further: Corticosteroids confer an RR of 1.78-1.99, and anti-TNF agents increase risk by RR 2.29 (95% CI: 1.52-3.45) 2
- Young immunocompromised adults face comparable or higher HZ risk than immunocompetent adults ≥50 years 3
FDA Authorization and ACIP Guidance
The FDA expanded Shingrix indication in 2021 to include adults aged ≥18 years who are or will be immunodeficient or immunosuppressed 4, 5. ACIP subsequently recommended RZV for adults ≥19 years who are immunocompromised 5. The Canadian NACI strongly recommends RZV for individuals 18 years and older who are or will be immunocompromised 3.
Safety Profile in IBD Patients
Real-world evidence demonstrates acceptable safety:
- A 2026 prospective study of 69 IBD patients (including those on advanced therapies) showed no serious vaccine-related adverse events and no significant changes in disease activity 6
- IBD clinical relapse occurred in only 5.8% of vaccinated versus 4.4% of unvaccinated patients (p=1.00) 6
- The FDA label notes that immunosuppressive therapies may reduce vaccine effectiveness but does not contraindicate use 4
Critical Caveats
Prior varicella vaccination does not eliminate the need for Shingrix. The vaccines serve different purposes:
- Varicella vaccine prevents primary chickenpox infection
- Shingrix prevents reactivation of latent varicella-zoster virus as herpes zoster 4
Timing considerations:
- Ideally administer before starting immunosuppression when possible
- If already on immunosuppressants, vaccinate anyway—the benefit outweighs reduced immunogenicity 2
- Complete the 2-dose series (doses separated by 2-6 months) for optimal protection
Rare but documented risks:
- Very small risk of Guillain-Barré Syndrome (estimated 3-6 excess cases per million doses in adults ≥65 years) 4
- Extremely rare case reports of disseminated VZV shortly after vaccination in severely immunocompromised patients 7, though causality remains uncertain
- These risks are vastly outweighed by the substantial risk of natural herpes zoster in immunosuppressed IBD patients
Practical Implementation
Administer the standard 2-dose intramuscular series (0.5 mL each dose, 2-6 months apart). Do not use the live attenuated zoster vaccine (Zostavax) in immunosuppressed patients—only the recombinant vaccine (Shingrix) is appropriate 2.